STAT+: Mental health apps can boost outcomes and lower costs, study finds

Developers of digital mental health treatments now have fresh economic data to help make the case for broader coverage of their apps.

Companies selling Food and Drug Administration-cleared apps for the treatment of psychiatric and other conditions have long struggled with adoption by patients, providers, and payers for many reasons. Clinical evidence supporting these prescription digital therapeutics has gradually improved, but policymakers and insurers have been hesitant to open the path to reimbursement too quickly.

Two new findings looking at the costs of adopting digital therapeutics may help inform their thinking.

Continue to STAT+ to read the full story…